Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 2
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 3(1)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00707057Phase 3Completed

Ibuprofen Extended-Release Dental Pain Study

Role: collaborator

NCT00559052Phase 2Completed

An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)

Role: collaborator

NCT00709215Phase 1Unknown

Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia

Role: collaborator

All 3 trials loaded